Efficacité de l’escalade de doses d’imatinib dans les LMC

[cousineg]

Efficacité de l’escalade de doses d’imatinib dans les LMC en échec après traitement à dose conventionnelle.
Voir http://www.france-hemato.net/rdp2.php?num=4373

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Voir http://bloodjournal.hematologylibrary.o ... type=HWCIT

[cousineg]

High dose imatinib improves cytogenetic and molecular remissions in pretreated Ph+/BCR-ABL+ CML chronic phase patients: first results from the randomized CELSG Phase III CML 11 "ISTAHIT" Study.
Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G.
Internal Medicine V, Haematology and Oncology, Medical University Innsbruck, Innsbruck, Austria,
9 Février 2010
‘’This is the first randomized phase III trial in pre-treated CP-CML patients demonstrating improvement in MCyR, CCyR and MMR rates with HD imatinib therapy.’’
Extrait de http://www.ncbi.nlm.nih.gov/pubmed/2014 ... dinalpos=1